Bayer DCA HbA1c waived testing — now marketed under the Siemens Healthineers brand — is a widely used point-of-care (POC) analyser that delivers rapid HbA1c results from a small capillary blood sample. Used across GP surgeries, community diabetes clinics, and pharmacies throughout the UK, the DCA Vantage supports timely clinical decisions in diabetes monitoring. This article explains how the system works, what CLIA waived status means in a UK context, who can operate the device, and how to interpret results in line with current NICE, NHS, and MHRA guidance.

What Is the Bayer DCA System and How Does It Measure HbA1c?

The Bayer DCA system uses latex-enhanced immunoassay turbidimetry to measure HbA1c from a 1 µL blood sample, delivering results in six to seven minutes; UK results must be reported in mmol/mol.

Have any more questions about this? Message our pharmaceutical team to get more info →

The Bayer DCA system — now marketed under the Siemens Healthineers brand following corporate acquisition — is a well-established point-of-care (POC) analyser designed to measure glycated haemoglobin (HbA1c) rapidly from a small capillary blood sample. The DCA Vantage and its predecessors have been widely used in clinical settings where near-patient testing is preferred over sending samples to a central laboratory.

The analyser works on the principle of immunoassay-based turbidimetry. A fingerstick or venous blood sample (typically 1 µL) is collected into a dedicated reagent cartridge. Inside the cartridge, haemoglobin is released from red blood cells and the HbA1c fraction is measured using latex-enhanced immunoassay technology. Results are typically available within six to seven minutes. Full details of the analytical method, sample requirements, turnaround times, and known limitations are set out in the Siemens DCA Vantage HbA1c Instructions for Use (IFU), which operators should consult before use.

In the UK, results must be reported in mmol/mol (IFCC units) in line with NHS and NICE guidance; the percentage (NGSP/DCCT) format may be shown alongside for reference where clinically helpful, but mmol/mol is the standard.

It is important to note that the DCA system measures HbA1c specifically and does not provide a full blood count or assess other haemoglobin variants. HbA1c measurement — whether by POC device or laboratory method — is not appropriate for diagnosis or monitoring in certain clinical situations, including pregnancy, children and young people, suspected type 1 diabetes, known haemoglobinopathies or other conditions causing altered red-cell survival (e.g., haemolytic anaemia, iron-deficiency anaemia, recent blood transfusion), stage 4–5 chronic kidney disease (CKD), HIV infection, and acute illness. In these circumstances, laboratory-based methods such as HPLC, or alternative diagnostic tests such as plasma glucose, should be used. Clinicians should refer to NICE NG28 and the UK/WHO-aligned position statement on the use of HbA1c in the diagnosis of diabetes for full guidance on exclusions.

CLIA Waived Status and What It Means for Point-of-Care Testing

CLIA waived status is a US regulatory designation with no direct legal standing in the UK; UK POC devices are regulated under the UK Medical Devices Regulations 2002 and overseen by the MHRA.

The term CLIA waived refers to a classification under the United States Clinical Laboratory Improvement Amendments (CLIA) of 1988. Tests granted waived status by the US Food and Drug Administration (FDA) are considered simple to perform, with a low risk of erroneous results, and are therefore exempt from the more stringent proficiency testing and quality oversight requirements applied to moderate- or high-complexity laboratory tests in the US. The Bayer (Siemens) DCA system has received CLIA waived status for HbA1c testing in the United States.

CLIA waived status is a US regulatory designation and has no direct legal or regulatory standing in the United Kingdom. It is referenced here because it appears in product literature and is sometimes cited by healthcare professionals familiar with US practice, but UK practitioners should not interpret it as conferring any specific regulatory approval or reduced governance obligation in the UK.

In Great Britain, point-of-care testing (POCT) devices are regulated as in vitro diagnostic (IVD) medical devices under the UK Medical Devices Regulations 2002 (as amended). Devices may currently bear CE marking under transitional arrangements or UKCA marking; manufacturers and suppliers should be consulted regarding current conformity status. Northern Ireland continues to follow the EU IVD Regulation (IVDR 2017/746). Up-to-date guidance on device conformity and post-market obligations is available from the MHRA.

For NHS POCT services, the expectation is accreditation to ISO 15189 (incorporating ISO 22870 for point-of-care testing) through the United Kingdom Accreditation Service (UKAS). Professional governance is provided by the Association for Clinical Biochemistry and Laboratory Medicine (ACB) and the Royal College of Pathologists (RCPath), whose Point of Care Testing Good Practice Guidelines set out requirements for POCT committees, operator training, quality control, and audit.

The CLIA waived designation does serve as a useful indicator that the DCA system is designed for use by non-laboratory-trained staff — a principle that aligns with UK POCT governance — but this does not reduce the obligation to comply with UK regulatory and quality requirements.

Using the DCA Analyser in UK Clinical and Community Settings

The DCA analyser is used for diabetes monitoring in GP surgeries, community clinics, and pharmacies, but must not be used for diagnosing type 2 diabetes, which requires a quality-assured laboratory venous sample.

In the UK, the DCA analyser is used across a range of clinical environments, including GP surgeries, community diabetes clinics, hospital outpatient departments, and community pharmacies. Its ability to deliver rapid HbA1c results supports timely clinical decisions, such as adjusting diabetes medication, initiating insulin therapy, or identifying individuals who may require further assessment during a single patient consultation.

Important: In the UK, HbA1c used for the diagnosis of type 2 diabetes must be measured on a venous blood sample analysed in a quality-assured laboratory. POCT HbA1c devices, including the DCA system, are not recommended for diagnostic use. Where an asymptomatic individual has a laboratory HbA1c result of 48 mmol/mol or above, a second confirmatory laboratory HbA1c (or plasma glucose test) is required before a diagnosis of type 2 diabetes is made. This requirement is set out in NICE NG28 and the UK/WHO-aligned position statement on the use of HbA1c in the diagnosis of diabetes mellitus.

HbA1c should not be used for diagnosis in the following groups, regardless of whether testing is performed by POC device or in a laboratory:

• Pregnant women

• Children and young people

• Individuals with suspected type 1 diabetes

• People with haemoglobinopathies, haemolytic anaemia, iron-deficiency anaemia, or other conditions causing altered red-cell survival

• People who have received a recent blood transfusion

• Individuals with stage 4–5 CKD

• People living with HIV

• Those who are acutely unwell

In these situations, plasma glucose testing or specialist laboratory methods should be used.

For monitoring of glycaemic control in people with established diabetes, the DCA system is well suited to:

• Routine diabetes reviews in primary care

• Structured education programmes such as DESMOND or X-PERT

• Community outreach clinics serving populations with limited access to laboratory services

• Pharmacy-led diabetes management services

Clinical governance requirements in the UK mean that any site using the DCA analyser must have a documented POCT policy, a designated POCT lead, and participation in an approved external quality assurance (EQA) scheme, such as those provided by UK NEQAS for HbA1c. These requirements ensure that results generated outside the laboratory meet the same standards of accuracy and reliability as those produced in accredited laboratories.

Accuracy, Quality Assurance, and Regulatory Requirements for HbA1c Testing

UK sites must participate in UK NEQAS for HbA1c, run internal quality controls, and seek UKAS accreditation to ISO 15189/22870; device malfunctions must be reported to the MHRA via the Yellow Card scheme.

The accuracy of HbA1c measurement is critical, as results directly influence monitoring and treatment decisions for millions of people living with diabetes in the UK. The DCA Vantage analyser has demonstrated good analytical performance in peer-reviewed studies, with results generally meeting NGSP/IFCC standardisation benchmarks. Performance in EQA schemes such as UK NEQAS for HbA1c provides the most relevant ongoing indicator of accuracy for UK clinical sites. As with all POC devices, performance can be affected by operator technique, storage conditions, and reagent cartridge handling; the Siemens DCA Vantage HbA1c IFU should be consulted for full performance specifications and known interferences.

In Great Britain, all IVD medical devices — including the DCA system — must comply with the UK Medical Devices Regulations 2002 (as amended), with UKCA or CE marking under current transitional arrangements. Northern Ireland follows the EU IVDR 2017/746. The MHRA provides guidance on device conformity, post-market surveillance, and reporting obligations. Any malfunction or adverse incident involving a POC device should be reported to the MHRA via the Yellow Card scheme for medical devices.

NHS POCT services are expected to seek UKAS accreditation to ISO 15189, incorporating ISO 22870 for point-of-care testing. Governance should be overseen by a POCT committee with a designated POCT lead, in line with RCPath/ACB Point of Care Testing Good Practice Guidelines.

Ongoing quality assurance at each clinical site must include:

• Internal quality control (IQC): Running validated control materials at regular intervals to verify the analyser is performing within acceptable limits

• External quality assurance (EQA): Participation in UK NEQAS for HbA1c, enabling comparison of results against peer laboratories and identification of systematic errors

• Operator training records and documented competency assessments

• Audit of POCT processes and results against agreed standards

The MHRA advises that any POC testing device showing inconsistent or out-of-range quality control results should be taken out of service until the issue is investigated and resolved. Clinicians should refer to the manufacturer's IFU for a full list of known interferents — including high triglyceride levels, hyperbilirubinaemia, and haemoglobin variants — and should apply appropriate clinical judgement when results are unexpected or inconsistent with the clinical picture.

Who Can Perform POCT HbA1c and What Training Is Required?

All DCA operators must complete documented training covering device operation, quality control, troubleshooting, and result interpretation, with competency reassessed at least annually per RCPath/ACB and UKAS ISO 22870 requirements.

One of the principal advantages of the DCA system is that it is designed to be operated by non-laboratory-trained healthcare professionals, including practice nurses, healthcare assistants, pharmacists, and diabetes specialist nurses. This accessibility is central to its value in primary and community care settings. However, ease of use does not eliminate the need for formal training and ongoing competency assessment.

In the UK, the RCPath/ACB Point of Care Testing Good Practice Guidelines and UKAS ISO 22870 requirements stipulate that all operators of POC devices must receive documented training before using the device unsupervised. Training should cover:

• Device operation: Sample collection, cartridge handling, and result retrieval

• Quality control procedures: How to run IQC samples and interpret results

• Troubleshooting: Recognising error codes and knowing when to escalate or take the device out of service

• Result interpretation: Understanding HbA1c units (mmol/mol as the UK standard, with % for reference where needed) and relevant clinical thresholds

• Data recording: Entering results into the patient record and the POC device log in line with local and national data governance requirements

Competency should be reassessed at least annually, or following any significant change in device software, reagent lot, or clinical role. Sites should maintain a training register, and the POCT lead is responsible for ensuring all operators remain competent. The Care Quality Commission (CQC) may review POCT governance arrangements as part of inspection of primary care and community services.

For community pharmacy settings, the General Pharmaceutical Council (GPhC) standards for pharmacy professionals and NHS commissioning bodies may have additional requirements for service accreditation. Pharmacists and pharmacy technicians undertaking HbA1c testing should ensure their service is covered by appropriate clinical governance frameworks and professional indemnity arrangements. Patient consent and data protection obligations under UK GDPR must be observed, and results should be integrated into the patient's clinical record in line with local information governance policies.

Interpreting HbA1c Results and Next Steps for Diabetes Management

UK HbA1c thresholds are: below 42 mmol/mol (normal), 42–47 mmol/mol (prediabetes — refer to NHS DPP), and 48 mmol/mol or above (consistent with type 2 diabetes — requires confirmatory laboratory test in asymptomatic individuals).

HbA1c reflects average blood glucose levels over the preceding two to three months, corresponding to the lifespan of red blood cells. In the UK, results are reported in mmol/mol (IFCC units); some older literature and US-based resources use the percentage (NGSP/DCCT) format. Clinicians should be familiar with both to avoid misinterpretation when reviewing records from different healthcare systems.

NICE NG28-aligned thresholds for interpreting HbA1c results are as follows:

• Below 42 mmol/mol: Within the normal range — diabetes unlikely

• 42–47 mmol/mol: Non-diabetic hyperglycaemia (prediabetes) — lifestyle intervention and referral to the NHS Diabetes Prevention Programme (NHS DPP) recommended

• 48 mmol/mol or above: Consistent with a diagnosis of type 2 diabetes — confirmation with a second laboratory HbA1c (or plasma glucose test) is required in asymptomatic individuals before a diagnosis is made

Note that HbA1c should not be used for diagnosis in the groups listed in the section above (including pregnancy, children and young people, suspected type 1 diabetes, haemoglobinopathies, altered red-cell turnover, CKD 4–5, HIV, and acute illness). In these circumstances, plasma glucose testing or specialist laboratory methods are appropriate.

For monitoring glycaemic control in established type 2 diabetes, NICE NG28 recommends individualised targets:

• 48 mmol/mol is a reasonable target for most people managed with lifestyle measures or medications not associated with hypoglycaemia

• 53 mmol/mol is an appropriate target for people treated with a sulphonylurea or insulin, where a lower target would carry an unacceptable risk of hypoglycaemia

• Higher targets may be appropriate for frail or elderly patients, or where tight control is not in the individual's best interest; targets should be agreed in shared decision-making with the patient

Following a DCA HbA1c result in the prediabetes range, the appropriate next step is referral to the NHS Diabetes Prevention Programme (NHS DPP), subject to national eligibility criteria, alongside lifestyle counselling. A result consistent with type 2 diabetes should trigger a full clinical assessment — including renal function, lipid profile, blood pressure measurement, and discussion of treatment options — in line with NICE NG28.

Patients should be advised to contact their GP or diabetes team promptly if they experience symptoms of hyperglycaemia (excessive thirst, polyuria, fatigue, blurred vision) or hypoglycaemia between scheduled reviews. Regular HbA1c monitoring — typically every three to six months when treatment is being adjusted, and every six to twelve months once stable — remains a cornerstone of effective long-term diabetes management, as recommended by NICE NG28.

Frequently Asked Questions